PolyPeptide Group (PPGN.SW)

Executive Summary

PolyPeptide Group is a leading Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in peptide and oligonucleotide synthesis. Founded in 1952, the company has a strong track record in custom peptide synthesis, generic peptides, and GMP manufacturing. As a public company listed on SIX Swiss Exchange (PPGN.SW), PolyPeptide serves a global customer base in the pharmaceutical and biotechnology sectors. The company has benefited from the surging demand for peptide-based therapeutics, particularly GLP-1 receptor agonists for diabetes and obesity, which have driven significant capacity expansion and contract wins. PolyPeptide's recent financial performance reflects margin pressures from capacity investments, but its long-term growth outlook remains robust given the secular shift toward peptide drugs.

Upcoming Catalysts (preview)

• Q2 2026New Long-Term Supply Agreement for GLP-1 API60% success
• Q3 2026Completion of Capacity Expansion at Malmö Facility80% success
• Q4 2026FDA Approval of Customer Peptide Drug Manufactured by PolyPeptide35% success